278 related articles for article (PubMed ID: 19557769)
1. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
2. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
3. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
4. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
Tefferi A; Mesa RA; Pardanani A; Hussein K; Schwager S; Hanson CA; Steensma DP
Am J Hematol; 2009 May; 84(5):265-7. PubMed ID: 19396855
[TBL] [Abstract][Full Text] [Related]
5. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
Leitch HA; Chan C; Leger CS; Foltz LM; Ramadan KM; Vickars LM
Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
[TBL] [Abstract][Full Text] [Related]
7. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
8. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
Kim YR; Kim JS; Cheong JW; Song JW; Min YH
Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
[TBL] [Abstract][Full Text] [Related]
9. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
10. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
[TBL] [Abstract][Full Text] [Related]
11. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
12. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
13. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
[TBL] [Abstract][Full Text] [Related]
14. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
Tefferi A; Huang J; Schwager S; Li CY; Wu W; Pardanani A; Mesa RA
Cancer; 2007 May; 109(10):2083-8. PubMed ID: 17407134
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Wong SA; Leitch HA
Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
[TBL] [Abstract][Full Text] [Related]
16. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
[TBL] [Abstract][Full Text] [Related]
17. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
[TBL] [Abstract][Full Text] [Related]
18. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
[TBL] [Abstract][Full Text] [Related]
19. Early massive transfusion in trauma patients: Canadian single-centre retrospective cohort study.
Mahambrey TD; Fowler RA; Pinto R; Smith TS; Callum JL; Pisani NS; Rizoli SB; Adhikari NK
Can J Anaesth; 2009 Oct; 56(10):740-50. PubMed ID: 19641979
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features and prognostic factors in primary myelofibrosis patients under 45 years old].
Lu L; Xiao ZJ; Chen HS; Lin H; Han ZC
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):281-4. PubMed ID: 15949290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
